doripenem has been researched along with Pneumonia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaniga, K; Lee, M; Redman, R; Rice, DA | 1 |
| Haruyama, S; Nakamura, M; Ohmori, S; Okada, E; Sawada, Y; Shibata, M; Yamaguchi, T; Yoshioka, M | 1 |
| Mandell, L | 1 |
| Akhras, K; Caro, JJ; Kongnakorn, T; Merchant, S; Mwamburi, M; Nathwani, D | 1 |
| Apisarnthanarak, A; Apisarnthanarak, P; Kiratisin, P; Mundy, LM | 1 |
| De Waele, JJ; Lipman, J; Paterson, DL; Roberts, JA; Udy, AA | 1 |
1 review(s) available for doripenem and Pneumonia
| Article | Year |
|---|---|
Doripenem: a new carbapenem in the treatment of nosocomial infection.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Humans; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
1 trial(s) available for doripenem and Pneumonia
| Article | Year |
|---|---|
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem; Intraabdominal Infections; Male; Meropenem; Ofloxacin; Pneumonia; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
5 other study(ies) available for doripenem and Pneumonia
| Article | Year |
|---|---|
Maculopapular eruption caused by doripenem.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Pneumonia | 2017 |
Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Humans; Pneumonia; United States | 2010 |
Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Rectum; Stenotrophomonas maltophilia; Thienamycins | 2011 |
What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Critical Illness; Cross Infection; Doripenem; Humans; Kidney; Metabolic Clearance Rate; Pneumonia; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic | 2012 |
Doripenem (doribax)--a new parenteral carbapenem.
Topics: Carbapenems; Cross Infection; Doripenem; Female; Humans; Pneumonia; Pneumonia, Ventilator-Associated; Urinary Tract Infections | 2008 |